What we’re looking for

The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for mental health conditions, in particular:

  • psychotic disorders
  • affective disorders
  • cognitive disorders
  • psychiatric symptoms associated with dementia

The Psychiatry Consortium intend to fund projects which:

  • are supported by robust evidence that links the molecular target to human disease, which can be further developed or validated,
  • provide a sound therapeutic hypothesis of how target modulation may have a therapeutic effect,
  • will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability

Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.

The call for proposals is now closed

Sign up to the newsletter to be notified of future call dates

Sign up

What we will NOT fund:

  • projects focused on well-studied targets and pathways for psychiatry diseases
  • projects with advanced chemistry e.g. lead/candidate molecules already synthesised and requiring only in vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
  • non-pharmacological interventions
  • purely academic explorations of new animal or cellular models (unless there is a clear drug discovery application, e.g. using the model as a tool for validating a new target)
  • early target identification studies without a proposed target (i.e. projects that are mostly characterization and/or hypothesis generating studies)
  • repurposing of existing drugs (unless as a method for validating new molecular targets)
  • clinical trials or clinical studies requiring prospective collection of human samples

What we will offer:

The research projects we support are collaborative in nature, with involvement from the Psychiatry Consortium members in devising the final project plan.

The Psychiatry Consortium will provide the successful applicants access to:

  • drug-discovery expertise
  • drug-discovery capabilities, through specialised Partner Organisations
  • commercial know-how
  • project management resources
  • project funding